About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $130.8B. The stock trades at 14.13x trailing earnings and yields 3.96%.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $130.8B
- P/E ratio
- 14.13
- EPS (TTM)
- $3.46
- Revenue (TTM)
- $48.2B
- Free cash flow
- $12.8B
- Profit margin
- 14.6%
- Dividend yield
- 3.96%
- Shares outstanding
- 2B
Financial health: Fair7/10
6 strengths, 2 concerns. Weakest points: debt to equity, revenue growth.
- Debt to equity: 2.43 (Concern, benchmark < 0.5) — Debt of 2.43x equity is high against the 0.5x benchmark. It has deteriorated over the last 4 years.
- Net debt vs cash flow: 2.7y (Strong, benchmark < 4 years) — Net debt of $34.2B is 2.7x annual free cash flow — about 3 years of cash flow to repay.
- Current ratio: 1.26 (Watch, benchmark > 1.5) — Short-term assets cover 1.26x short-term liabilities, against Graham's 1.5x floor. It has been broadly flat over the last 4 years.
- Return on equity: 38.2% (Strong, benchmark > 15%) — Earns 38.2% on shareholder equity, comfortably past the > 15% mark.
- Gross margin: 69.2% (Strong, benchmark > 40%) — Keeps 69.2% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: 14.6% (Strong, benchmark > 10%) — Turns 14.6% of revenue into profit, comfortably past the > 10% mark.
- Free cash flow: $12.8B (Strong, benchmark positive) — Generated $12.8B of free cash flow after capital spending. It has been broadly flat over the last 4 years.
- Revenue growth: -0.2% (Concern, benchmark > 10%) — Revenue changed -0.2% year on year, well short of the > 10% mark.
- Earnings growth: 178.8% (Strong, benchmark > 10%) — Earnings changed 178.8% year on year, comfortably past the > 10% mark.
- Payout ratio: 71.5% (Watch, benchmark < 60%) — Pays out 71.5% of earnings as dividends — above the level usually considered sustainable.